Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Launched by UNIVERSITY HOSPITAL, CAEN · Feb 1, 2024

Keywords

ClinConnect Summary

The LenALL clinical trial is studying a rare but serious condition called Acute Lymphoblastic Leukaemia (ALL) that may occur in some patients who are treated with a medication called lenalidomide (LEN), which is used for various cancers. The goal of the trial is to gather more information about cases of ALL related to LEN by looking at reports in a database maintained by the World Health Organization. Currently, not much is known about this potential side effect, and this research aims to shed light on it.

To participate in this trial, you must be between the ages of 65 and 74 and have been treated with lenalidomide. The trial is still in the planning stages and is not yet recruiting participants. If you qualify, you will help researchers understand the relationship between LEN and ALL, which could lead to improved safety for patients in the future. It's important to note that only specific cases are being looked at, so not everyone treated with LEN will be included. Your involvement could contribute to valuable insights in cancer treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Case reported in the World Health Organization (WHO, also called VigiBase) at the time of the extraction
• • Patients treated with at least LEN (L04AX04)
• Exclusion Criteria:
• • -Chronology not compatible between LEN and ALL